Novo Nordisk raises full-year outlook again as it accelerates Wegovy pill rollout
The third guidance lift this year signals that oral GLP-1 demand is holding up even as Eli Lilly widens its lead in the weight-loss market.
Read at Reuters →Full coverage · 5 outlets
- Reuters · lead
- BioPharma DiveNovo gets much-needed lift as Wegovy pill tops Wall Street forecasts
- The Pharma LetterNovo raises full-year outlook on continued GLP-1 momentum
- Tech TimesWegovy Pill Outperforms Foundayo as Medicare Drives Novo’s Third Guidance Lift
- MSNNovo Nordisk raises 2026 outlook as Wegovy pill shines